Skip to main content

Home/ health information/ Group items tagged ABPI-report

Rss Feed Group items tagged

pharmacybiz

ABPI suspends Novo Nordisk's membership for two years - 0 views

  •  
    The Association of the British Pharmaceutical Industry (ABPI) has suspended the membership of Novo Nordisk for two years due to serious breaches of its Code of Practice. The action was taken by the ABPI Board following an investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the ABPI Code of Practice, including Clause 2 which deals with actions "likely to bring discredit on, or reduce confidence in, the pharmaceutical industry". Having considered the case and requesting a further detailed audit of Novo Nordisk's compliance processes, the ABPI Board decided to suspend Novo Nordisk from ABPI membership. Susan Rienow, President-Elect, ABPI, said: "The ABPI Board has carefully considered the PMCPA's case report into Novo Nordisk and the subsequent audit of their compliance procedures. "The Board expressed significant concern about Novo Nordisk's compliance activities and the very serious issues identified. As a result, the ABPI Board have taken the decision to suspend Novo Nordisk from ABPI membership.
pharmacybiz

ABPI calls for equal access treatments for cancer patients - 0 views

  •  
    The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials. The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients. David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care. "We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.
pharmacybiz

ABPI Report Urges NHS to Prepare for Future Advanced Therapies | Transforming Patient C... - 0 views

  •  
    A new report from the Association of the British Pharmaceutical Industry (ABPI) has highlighted that while the NHS has made significant progress in the introduction of cell and gene therapies, the health service must "do more to get ready for the arrival of the advanced therapies of the future." The ABPI noted that advanced therapies, also known as Advanced Therapy Medicinal Products (ATMPs), offer hope for diseases previously deemed "untreatable." ATMPs have already been introduced for treating some rarer conditions, including haemophilia, spinal muscular atrophy, and a rare disease that causes blindness. "In some cases, these therapies can transform people's lives with just a single treatment," the Association said. The ABPI's report, titled Unlocking Access to Future ATMPs in the UK: Comparing International Approaches, emphasises the need for the NHS to revise its payment strategies for upcoming therapies.
pharmacybiz

Public Willing to Pay More for Medicines for Severe Conditions, New Report Reveals | AB... - 0 views

  •  
    A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.
pharmacybiz

NHS can improve equality of access to innovative medicines - 0 views

  •  
    The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the collaboration between industry and the NHS to improve patient outcomes across the UK. Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these areas continues to be below the average of similar countries in Europe. The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations and industry have helped to tackle unwarranted variation in the uptake of innovative medicines. Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment. The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.
pharmacybiz

UK Pharmaceutical Industry Gains Trust Amid Pandemic: Study - 0 views

  •  
    The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.
pharmacybiz

UK Life Sciences : New Report 2024 Uncovers Challenges & Opportunities - 0 views

  •  
    "The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.
pharmacybiz

Rising VPAS Rates: Impact on NHS UK Budgets - 0 views

  •  
    The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million from their budgets annually for the next five years due to the spiralling tax rates. The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said in its white paper released on Monday (October 30). The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets. BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars annually - a consequence of reduced competition.
1 - 8 of 8
Showing 20 items per page